Esperion shares surge as FDA waves off panel review; Adaptimmune buoyed by a positive data snapshot

Derek Archila

? Esperion got a 15% bump on its stock price $ESPR this morning after the biotech reported that the FDA had said it didn?t expect to call an advisory panel together to review the newly accepted NDAs for bempedoic acid (BPA) and their bempedoic acid/ezetimibe combination tablet. Investors sa